ASH 2018 | Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
Carol Moreno, MD, PhD, of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, gives an overview of the Phase III iLLUMINATE trial (NCT02264574), which showed an improved progression-free survival, as well as higher response rates with ibrutinib-obinutuzumab vs. chlorambucil-obinutuzumab as a first-line treatment for chronic lymphocytic Leukemia (CLL). Dr Moreno also introduces other studies investigating various combinations with ibrutinib, including venetoclax and CAR T-cells, pushing towards better CLL treatments compared with the current standard of care. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Related videos
04:20
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
04:20
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
04:20
An exciting era for CAR T-cell therapy
Mohamad Mohty
04:20
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
04:20
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
